

Resource Summary Report

Generated by [PRECISE-TBI](#) on Aug 10, 2026

Santa Cruz Biotechnology

RRID:SCR_008987

Type: Tool

Proper Citation

Santa Cruz Biotechnology (RRID:SCR_008987)

Resource Information

URL: <https://www.scbt.com/scbt/home/>

Proper Citation: Santa Cruz Biotechnology (RRID:SCR_008987)

Description: An Antibody supplier

Synonyms: Santa Cruz Biotechnology inc., SantaCruz, Santa Cruz

Resource Type: commercial organization

Resource Name: Santa Cruz Biotechnology

Resource ID: SCR_008987

Alternate IDs: nlx_152453

Record Creation Time: 20220129T080250+0000

Record Last Update: 20260808T185911+0000

Ratings and Alerts

No rating or validation information has been found for Santa Cruz Biotechnology.

No alerts have been found for Santa Cruz Biotechnology.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 42303 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Banerjee M, et al. (2026) FASN Inhibition Enhances the Efficacy of Chemotherapy in Colorectal Cancer by Inhibiting the DNA Damage Response. *Cancer research*, 86(10), 2522.

Gulla S, et al. (2026) MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer. *Cancer research*, 86(9), 2143.

Li H, et al. (2026) PDZRN4 suppresses lung adenocarcinoma progression via inhibiting ubiquitin-mediated HIF-1A degradation. *Oncogene*, 45(4), 577.

Vitale G, et al. (2026) Empowering the NSC-34 cell line as a motor neuron model: Cytosine arabinoside's action. *Neural regeneration research*, 21(1), 357.

Terzo S, et al. (2026) Positive impact of indicaxanthin from *Opuntia ficus-indica* fruit on high-fat diet-induced neuronal damage and gut microbiota dysbiosis. *Neural regeneration research*, 21(1), 324.

Clevenger AJ, et al. (2025) Oncogenic KRAS Mutations Confer a Unique Mechanotransduction Response to Peristalsis in Colorectal Cancer Cells. *Molecular cancer research : MCR*, 23(2), 128.

Thompson AD, et al. (2025) 5-Hydroxytryptamine 1F receptor loss reduces renal vasculature and prevents lasmiditan-induced recovery following moderate-severe acute kidney injury in mice. *American journal of physiology. Renal physiology*, 329(6), F834.

VandenHeuvel SN, et al. (2025) Decellularized Extracellular Matrix Scaffolds to Engineer the Dormant Landscape of Microscopic Colorectal Cancer Liver Metastasis. *Advanced healthcare materials*, e01791.

Kesh K, et al. (2025) Targeting Triple-Negative Breast Cancer with Momordicine-I for Therapeutic Gain in Preclinical Models. *Cancers*, 17(14).

Maurya SK, et al. (2025) Mucin 5AC Promotes Breast Cancer Brain Metastasis through cMET/CD44v6. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(5), 921.

Lafargue A, et al. (2025) Twist1-induced suppression of oncogene-induced senescence in non-small cell lung cancer requires the transactivation domain of Twist1. *Neoplasia (New York, N.Y.)*, 66, 101179.

Hori A, et al. (2025) Blockade of insulin receptor signaling in the medullary cardiovascular centers impairs open-loop arterial baroreflex function via attenuated neural arc in healthy male rats. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 39(5), e70421.

Yang SA, et al. (2025) Amelioration of Astrocytic Dysfunction via AQP4/LRP1 Pathway by *Zizania latifolia* and Tricin in C6 Cells Exposed to Amyloid β and High-Dose Insulin and in Mice Treated with Scopolamine. *Journal of microbiology and biotechnology*, 35,

e2412026.

Wang P, et al. (2025) p85 γ acts as a transcription cofactor and cooperates with BCLAF1 in the nucleus. *Nature communications*, 16(1), 2042.

Vecchio E, et al. (2025) FABP5 is a key player in metabolic modulation and NF- κ B dependent inflammation driving pleural mesothelioma. *Communications biology*, 8(1), 324.

Tian S, et al. (2025) Menin inhibitor MI-503 exhibits potent anti-cancer activity in osteosarcoma. *Scientific reports*, 15(1), 7059.

He LN, et al. (2025) Tetrandrine augments melanoma cell immunogenicity via dual inhibition of autophagic flux and proteasomal activity enhancing MHC-I presentation. *Acta pharmacologica Sinica*, 46(7), 2056.

Zuidhof HR, et al. (2025) The m6A demethylase FTO promotes C/EBP β -LIP translation to perform oncogenic functions in breast cancer cells. *The FEBS journal*, 292(10), 2688.

Upadhyay S, et al. (2025) Dual nuclear receptor 4A1 (NR4A1/NR4A2) ligands inhibit glioblastoma growth and target TWIST1. *Molecular pharmacology*, 107(2), 100009.

Lee HS, et al. (2025) Lupenone preserves T cell activity by recovery of CD40L expression and protection from cytotoxicity due to methamphetamine exposure. *PloS one*, 20(3), e0314054.